Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine kinase inhibitor that has shown benefit in various ...

A number of agents have antitumor activity in metastatic renal cancer. Most of the new agents are approved based on a comparison with either interleukin 2 or interferon α. But on what basis does the ...

This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in patients with advanced solid tumours. Two schedules with ...

The appraisal committee considered evidence submitted by the manufacturer of sunitinib and a review of this submission by the evidence review group (ERG). In the submission, the manufacturer presented ...

Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...

A strategy for giving intermittent, high doses of the anti-cancer drug sunitinib is well-tolerated by patients with advanced cancer and increases concentrations of the drug in tumours, which is ...

A total of 289 patients were enrolled. Median age at diagnosis was 58.7 years. The patient characteristics were as follows: 73.6% of patients were males; 85.8% had clear-cell renal cell carcinoma (RCC ...

The use of the tyrosine kinase inhibitor (TKI) sunitinib (Sutent) significantly improved progression-free survival (PFS) in patients with malignant pheochromocytoma and paraganglioma (PPGL), an ...

Sunitinib malate is a multitargeted tyrosine kinase inhibitor approved for the treatment of advanced renal-cell carcinoma. We report on an asymptomatic increase in the mean corpuscular volume of ...

A warning about serious skin reactions, some of which have been fatal, has been issued in Canada for sunitinib (Sutent, Pfizer). These serious skin reactions have been "very rarely reported," but some ...

Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Sunitinib Malate - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Sunitinib Malate ...

4 Evidence and interpretation The Appraisal Committee considered evidence from a number of sources. The following sections are based on the evidence received for the appraisal of 'bevacizumab, ...